Leukemia News

Daily electronic patient-reported outcome assessments may provide valuable insight into symptom management among patients with cancer undergoing antineoplastic treatment, according to a study published in JAMA Network Open.

The FDA granted priority review to ivosidenib tablets in combination with azacitidine for previously untreated IDH1-mutated acute myeloid leukemia.

Childhood acute leukemia survivors with Down syndrome had increased risk for late mortality not attributable to cardiac- or subsequent malignant neoplasm-associated late effects, according to study results published in Cancer.

The FDA granted orphan drug designation to mocravimod for treatment of patients with acute myeloid leukemia who are undergoing allogeneic hematopoietic stem cell transplantation.

Adding romidepsin to busulfan and fludarabine reduced incidence of relapse among patients receiving allogeneic stem cell transplant for aggressive T-cell malignancies, according to results of a phase 1/phase 2 study.

Researchers have developed a novel quantitative assay that can predict which patients will achieve durable remissions after CD19-directed chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma.

Amit Maity, MD, PhD, has been appointed chair of the department of radiation oncology for Spencer Fox Eccles School of Medicine at University of Utah.

ASH announced the 36 recipients of the society’s 2022 Scholar Awards.

More than 60% of patients with relapsed or refractory B-cell acute lymphoblastic leukemia achieved initial complete remission after receiving an investigational chimeric antigen receptor T-cell therapy, phase 1/phase 2 study results showed.

The FDA granted fast track designation to IO-202 for treatment of relapsed or refractory acute myeloid leukemia.